Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025

  • ID: 4394889
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Actavis
  • Astellas Pharmaceuticals
  • AstraZenenca
  • GlaxoSmithKline
  • Pfizer
  • Salix Pharmaceuticals Ltd
  • MORE

The irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 780.29 Mn by 2025, expanding at a CAGR of 13.89% from 2017 - 2025.

Market Insights

Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as breakthrough step in the long struggle to discover effective treatment for IBS-D.

Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due to the introduction of the said novel drugs.

Geographically, North America is the largest market for IBS-D drugs. Higher awareness about the disease, expected prompt availability of the newly approved drugs, better reimbursement system and higher IBS prevalence are the prime factors that drive the IBS-D drugs market in North America. On the other hand, Asia Pacific is expected to be the fastest growing regional market for IBS-D drugs. It is estimated that Asia Pacific market will progress at a CAGR of approximately 17% during the forecast period 2016-2022. Japan with its largest pool of geriatric population and with the anticipated approval for Xifaxan in 2018 makes the country the largest national market in Asia Pacific region. In addition, it is also estimated that due to factors such as moderate purchasing power in the patient population, lower diagnosis rates and poor disease awareness will contribute to sustained demand for OTC IBS-D drugs in the region. Regions such as Latin America and MENA are believed to follow the trends in Europe and North America market.

Commenting on the competitive scenario, the IBS-D drugs market is fragmented with no clear leader in terms of market revenue share. However, it is expected that with gradual approvals in the international markets, Valeant (Salix Pharmaceuticals) will emerge the market leader in the overall IBS drugs market with products for both IBS-D and IBS-C treatment.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actavis
  • Astellas Pharmaceuticals
  • AstraZenenca
  • GlaxoSmithKline
  • Pfizer
  • Salix Pharmaceuticals Ltd
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global IBS-D Drugs Market Portaiture
2.2 IBS-D Drugs Market, by Drug Type, 2017 Vs. 2022
2.3 IBS-D Drugs Market, by Prescription Type, 2017 (USD Mn)
2.4 IBS-D Drugs Market Share, by Geography, 2017 (Value %)

Chapter 3 IBS-D Drugs Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.1.1 Potential Patient Population
3.1.2 Prevalent Treatment Options for IBS-D
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Perpetual growth in IBS prevalence
3.2.2 Challenges
3.2.2.1 Low diagnosis rate and insufficient effect of drugs
3.2.3 Opportunities
3.2.3.1 Strong product pipeline
3.3 Attractive Investment Proposition
3.4 Competitive Analysis
3.4.1 Fractal Map Investigation

Chapter 4 Global IBS-D Drugs Market Analysis, by Drugs
4.1 Preface
4.2 Eluxadoline
4.3 Alosetron
4.4 Rifaximin
4.5 Loperamide
4.6 Diphenoxylate + Atropine
4.7 Dicyclomine and Hyoscyamine
4.8 Pipeline Drug Analysis: Ibodutant
4.9 Pipeline Drug Analysis: Ramosetron

Chapter 5 Global IBS-D Drugs Market Analysis, By Prescription Type
5.1 Prescribed and OTC Drugs
5.2 Prescribed Branded and Prescribed Generic Drugs

Chapter 6 Global IBS-D Drugs Market Analysis, By Geography
6.1 Preface
6.2 North America
6.2.1 United States
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.4.3 Rest of Asia Pacific
6.5 Rest of the World (RoW)

Chapter 7 Company Profiles
7.1 Astellas Pharmaceuticals
7.1.1 Overview
7.1.2 Astellas Pharmaceuticals Product Portfolio
7.1.3 SCOT Analysis
7.2 Actavis
7.2.1 Overview
7.2.2 Actavis product portfolio
7.2.3 Strategic Moves
7.2.4 SCOT Analysis
7.3 Pfizer
7.3.1 Overview
7.3.2 Pfizer Product Portfolio
7.3.3 SCOT Analysis
7.4 GlaxoSmithKline
7.4.1 Overview
7.4.2 GlaxoSmithKline Product Portfolio
7.4.3 SCOT Analysis
7.5 Salix Pharmaceuticals Ltd
7.5.1 Overview
7.5.2 Salix Pharmaceuticals Product Portfolio
7.5.3 SCOT Analysis
7.6 AstraZenenca
7.6.1 Overview
7.6.2 Astrazeneca Product Portfolio
7.6.3 SCOT Analysis

List of Figures
Fig. 1 IBS-D Drugs Market, by Drugs, 2017 Vs. 2022
Fig. 2 IBS-D Drugs Market, by Prescription Type, 2017 (USD Mn)
Fig. 3 IBS-D Drugs Market Share, by Geography, 2017 (Value %)
Fig. 4 IBS Physician Preference Insights
Fig. 5 Worldwide Prevalence of IBS Across Various Geographies
Fig. 6 Attractive Investment Proposition, IBS-D Drugs Market, 2017
Fig. 7 Fractal Map Investigation, Global IBS-D Drugs Market, by Key Players
Fig. 8 Global Eluxadoline (Viberzi) Market Revenue, 2017 - 2025 (USD Mn)
Fig. 9 Global Alosetron (Lotronex) Market Revenue, 2017 - 2025 (USD Mn)
Fig. 10 Global Rifaximin (Xifaxan) Market Revenue, 2017 - 2025 (USD Mn)
Fig. 11 Global Loperamide Market Revenue, 2017 - 2025 (USD Mn)
Fig. 12 Global Diphenoxylate + Atropine Market Revenue, 2017 - 2025 (USD Mn)
Fig. 13 Global Dicyclomine and Hyoscyamine Market Revenue, 2017 - 2025 (USD Mn)
Fig. 14 Canada IBS-D Drugs Market Revenue, 2013 - 2022 (USD Mn)
Fig. 15 U.K. IBS-D Drugs Market Revenue, 2017 - 2025 (USD Mn)
Fig. 16 Germany IBS-D Drugs Market Revenue, 2017 - 2025 (USD Mn)
Fig. 17 Rest of Europe IBS-D Drugs Market Revenue, 2017 - 2025 (USD Mn)
Fig. 18 China IBS-D Drugs Market Revenue, 2017 - 2025 (USD Mn)
Fig. 19 Japan IBS-D Drugs Market Revenue, 2017 - 2025 (USD Mn)
Fig. 20 Rest of Asia Pacific IBS-D Drugs Market Revenue, 2013 - 2022 (USD Mn)

List of Tables
Table 1 Global IBS-D Drugs Market Revenue, by Drugs, 2017 - 2025 (USD Mn)
Table 2 Global IBS-D Drugs Market Revenue, by Prescription Type, 2017 - 2025 (USD Mn)
Table 3 Global Prescribed IBS-D Drugs Market Revenue, (Branded and Generic Drugs), 2017 - 2025 (USD Mn)
Table 4 Global IBS-D Drugs Market Revenue, by Geography, 2017 - 2025 (USD Mn)
Table 5 North America IBS-D Drugs Market Revenue, by Country, 2017 - 2025 (USD Mn)
Table 6 U.S. IBS-D Drugs Market Revenue, by Drugs, 2017 - 2025 (USD Mn)
Table 7 U.S. IBS-D Drugs Market Revenue, by Prescription Type, 2017 - 2025 (USD Mn)
Table 8 U.S. Prescription IBS-D Drugs Market Revenue, (Branded & Generic Drugs), 2017 - 2025 (USD Mn)
Table 9 Europe IBS-D Drugs Market Revenue, by Country, 2017 - 2025 (USD Mn)
Table 10 Asia Pacific IBS-D Drugs Market Revenue, by Country, 2017 - 2025 (USD Mn)
Table 11 Rest of the World IBS-D Drugs Market Revenue, by Regions, 2017 - 2025 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astellas Pharmaceuticals
  • Actavis
  • Pfizer
  • GlaxoSmithKline
  • Salix Pharmaceuticals Ltd
  • AstraZenenca
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll